Skip to main content

Table 3 Mean daily dose of each csDMARD used in combination with abatacept in the ATTAIN, ASSURE, and ARRIVE studies

From: Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

 

Daily dose (mg)

ATTAIN

ASSURE

ARRIVE

Methotrexate

2.17

3.88

2.60

Hydroxychloroquine

364

323

383

Sulfasalazine

2597

2108

1866

Azathioprine

121

121

124

Leflunomide

18.2

19.9

19.4

  1. No data are available on the dose of individual csDMARDs used in the ACTION study
  2. csDMARD conventional synthetic disease-modifying antirheumatic drug
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us